GlassScriptPhysician profile
Christopher L Balinger
NPI 1467772517
$2,021.13
in general payments reported to CMS, 2019-2025
11 companies · $377 in 2025
The $377 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $437 · 2021: $302 · 2022: $172 · 2023: $331 · 2024: $271 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $450.97 | 2021-2025 | Xcm Biologic Tissue Matrix |
| Allergan, INC. | $391.30 | 2020-2022 | |
| Abbvie INC. | $346.53 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Revance Therapeutics, INC. | $236.57 | 2025 | Daxxify |
| Tepha INC | $191.53 | 2020 | |
| Galderma Laboratories, L.P. | $149.94 | 2020-2024 | |
| Wound Management Technologies, INC | $130.98 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $46.02 | 2023 | Exparel, Iovera |
| Acelrx Pharmaceuticals, INC. | $38.97 | 2020 | |
| Sanara Medtech INC. | $19.49 | 2020 | |
| Tela Bio, INC. | $18.83 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Balinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.